Artwork

内容由Dean and Ayesha Sherzai and Sherzai M.D.提供。所有播客内容(包括剧集、图形和播客描述)均由 Dean and Ayesha Sherzai and Sherzai M.D. 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

The New Alzheimer's Drug: Hope or a Massive Failure?

37:55
 
分享
 

Manage episode 295139115 series 2558094
内容由Dean and Ayesha Sherzai and Sherzai M.D.提供。所有播客内容(包括剧集、图形和播客描述)均由 Dean and Ayesha Sherzai and Sherzai M.D. 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Welcome to the Brain Health Revolution Podcast! In this episode, we took a deep dive into the history and steps of FDA approval of the latest Alzheimer's drug, Aducanumab. Developed by the biotechnology company, Biogen, it is the first approved drug that attempts to treat a possible cause of the neurodegenerative disease rather than just the symptoms. But the approval has sparked a contentious debate over whether the drug is effective. Many experts, including an independent panel of neurologists and biostatisticians, advised the FDA that clinical-trial data did not conclusively demonstrate that Aducanumab could slow cognitive decline. Yet patient advocacy groups tout this as a miracle drug and one that provides hope and opens the doors for future therapeutics for this devastating disease.

In this episode, we discuss:

- The history of drug development for Alzheimer's

- Amyloid and Tau protein targeting

- How this drug was presented in 2019, rejected, reapplication by Biogen, its reanalysis data and final approval by FDA on June 7, 2021

- Side effects of the drug

- Price and the economics around the drug

- Long term consequences to the field

Follow us:

https://teamsherzai.com

Instagram: @sherzaimd

Facebook: Sherzai MD

Twitter: @sherzaimd

  continue reading

81集单集

Artwork
icon分享
 
Manage episode 295139115 series 2558094
内容由Dean and Ayesha Sherzai and Sherzai M.D.提供。所有播客内容(包括剧集、图形和播客描述)均由 Dean and Ayesha Sherzai and Sherzai M.D. 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Welcome to the Brain Health Revolution Podcast! In this episode, we took a deep dive into the history and steps of FDA approval of the latest Alzheimer's drug, Aducanumab. Developed by the biotechnology company, Biogen, it is the first approved drug that attempts to treat a possible cause of the neurodegenerative disease rather than just the symptoms. But the approval has sparked a contentious debate over whether the drug is effective. Many experts, including an independent panel of neurologists and biostatisticians, advised the FDA that clinical-trial data did not conclusively demonstrate that Aducanumab could slow cognitive decline. Yet patient advocacy groups tout this as a miracle drug and one that provides hope and opens the doors for future therapeutics for this devastating disease.

In this episode, we discuss:

- The history of drug development for Alzheimer's

- Amyloid and Tau protein targeting

- How this drug was presented in 2019, rejected, reapplication by Biogen, its reanalysis data and final approval by FDA on June 7, 2021

- Side effects of the drug

- Price and the economics around the drug

- Long term consequences to the field

Follow us:

https://teamsherzai.com

Instagram: @sherzaimd

Facebook: Sherzai MD

Twitter: @sherzaimd

  continue reading

81集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南